Expanded ApoC-III Indications Could Reach 520,000 US Adults, Analysis Finds
Key Highlights
- Severe hypertriglyceridemia affected an estimated 1.63 million US adults, or 0.63% of the adult population.
- Approximately 520,000 adults met CORE/CORE2 criteria requiring triglycerides ≥500 mg/dL and background lipid-lowering therapy.
- An estimated 68.0% of adults with severe hypertriglyceridemia were not receiving lipid-lowering therapy.
- Under an assumed 20% triglyceride reduction with GLP-1 therapy, 36.3% remained eligible for both GLP-1 and potential expanded ApoC-III inhibitor treatment.
Expanding apolipoprotein C-III (ApoC-III) inhibitor indications beyond familial chylomicronemia syndrome could make approximately 520,000 US adults eligible for treatment, according to a national population-based analysis. The study also identified substantial gaps in background lipid-lowering therapy among adults with severe hypertriglyceridemia. The authors note that ApoC-III inhibitors include olezarsen. The findings were presented at the 2026 American Heart Association meeting.
Investigators examined potential treatment eligibility based on recent trial criteria and modeled how triglyceride reductions associated with glucagon-like peptide-1 (GLP-1) receptor agonist therapy might affect those estimates. The analysis addressed hypothetical expanded ApoC-III inhibitor indications rather than reporting outcomes from treatment initiation.
Researchers conducted a cross-sectional analysis of 11,153 adults participating in the National Health and Nutrition Examination Survey from 2011 through 2020. The sample represented approximately 258 million US adults. Trial-based eligibility followed CORE/CORE2 criteria: triglycerides ≥500 mg/dL plus background lipid-lowering therapy. GLP-1 eligibility was assessed using FDA-approved indications.
Sensitivity analyses assumed GLP-1–mediated triglyceride reductions of 15%, 20%, and 25% to estimate how many patients would retain ApoC-III inhibitor eligibility.
Study Findings
Severe hypertriglyceridemia, defined as triglycerides ≥500 mg/dL, affected 0.63% of US adults, corresponding to approximately 1.63 million people. Higher-risk hypertriglyceridemia, defined as triglycerides ≥880 mg/dL, affected approximately 360,000 adults. About 520,000 met CORE/CORE2 criteria requiring background lipid-lowering therapy. The investigators estimated that 68% of adults with severe hypertriglyceridemia were untreated and that 78.3% of those with higher-risk hypertriglyceridemia received no lipid-lowering therapy.
Under the moderate assumption of a 20% triglyceride reduction, modeled GLP-1 treatment would move 50.8% of patients with severe hypertriglyceridemia below the 500-mg/dL threshold. Meanwhile, 36.3% remained eligible for both GLP-1 therapy and ApoC-III inhibitors under expanded indications.
Clinical Implications
According to the authors, expanded ApoC-III inhibitor indications could substantially increase treatment eligibility, with greater use of background lipid-lowering therapy potentially increasing the eligible population further. They concluded that a significant proportion would retain eligibility despite modeled triglyceride reductions with GLP-1 therapy.
Expert Commentary
“Despite potential displacement by GLP1-mediated TG reduction, a significant proportion of US adults with sHTG would remain eligible for ApoC-III therapy under expanded indications,” the researchers concluded.
Reference
Kushmeliuk S, Prakash Y, Midha M, Choi D, Katragadda JK, Malick W. U.S. adults with severe hypertriglyceridemia: a national population-based analysis. Abstract presented at: American Heart Association 2026; November 7, 2026.
